These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30988610)

  • 1. Di-
    Briot T; Roger E; Bou Haidar N; Bejaud J; Lautram N; Guillet C; Thépot S; Legeay S; Lagarce F
    Int J Nanomedicine; 2019; 14():2091-2102. PubMed ID: 30988610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.
    Briot T; Roger E; Lautram N; Verger A; Clavreul A; Lagarce F
    Int J Nanomedicine; 2017; 12():8427-8442. PubMed ID: 29200853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.
    Michalski JM; Lyden ER; Lee AJ; Al-Kadhimi ZS; Maness LJ; Gundabolu K; Bhatt VR
    Future Oncol; 2019 Jun; 15(17):1989-1995. PubMed ID: 31170814
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted Lipid Nanoemulsions Encapsulating Epigenetic Drugs Exhibit Selective Cytotoxicity on CDH1
    Kim B; Pena CD; Auguste DT
    Mol Pharm; 2019 May; 16(5):1813-1826. PubMed ID: 30883132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
    Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
    Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
    Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-core nanocapsules as a nanomedicine for parenteral administration of tretinoin: development and in vitro antitumor activity on human myeloid leukaemia cells.
    Ourique AF; Azoubel S; Ferreira CV; Silva CB; Marchiori MC; Pohlmann AR; Guterres SS; Beck RC
    J Biomed Nanotechnol; 2010 Jun; 6(3):214-23. PubMed ID: 21179938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.
    Chilakala S; Feng Y; Li L; Mahfouz R; Quteba E; Saunthararajah Y; Xu Y
    Sci Rep; 2019 Mar; 9(1):4558. PubMed ID: 30872721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
    Santini V; Allione B; Zini G; Gioia D; Lunghi M; Poloni A; Cilloni D; Sanna A; Masiera E; Ceccarelli M; Abdel-Wahab O; Terenzi A; Angelucci E; Finelli C; Onida F; Pelizzari A; Ferrero D; Saglio G; Figueroa M; Levis A
    Leukemia; 2018 Feb; 32(2):413-418. PubMed ID: 28607470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid and TPGS based novel core-shell type nanocapsular sustained release system of methotrexate for intravenous application.
    Katiyar SS; Kushwah V; Dora CP; Jain S
    Colloids Surf B Biointerfaces; 2019 Feb; 174():501-510. PubMed ID: 30497012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
    Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
    Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
    Short NJ; Kantarjian HM; Loghavi S; Huang X; Qiao W; Borthakur G; Kadia TM; Daver N; Ohanian M; Dinardo CD; Estrov Z; Kanagal-Shamanna R; Maiti A; Benton CB; Bose P; Alvarado Y; Jabbour E; Kornblau SM; Pemmaraju N; Jain N; Gasior Y; Richie MA; Pierce S; Cortes J; Konopleva M; Garcia-Manero G; Ravandi F
    Lancet Haematol; 2019 Jan; 6(1):e29-e37. PubMed ID: 30545576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.